Executive Summary
This digest covers a single filing from Biocon Limited, a constituent of the S&P BSE PHARMA index, disclosed on October 9-10, 2026. The filing is a GST Order-in-Original for FY 2022-23 imposing a total quantified exposure of approximately Rs. 3.22 Cr (demand Rs. 1.85 Cr, interest Rs. 1.18 Cr, penalty Rs. 0.19 Cr).
The company states there is no material impact on financials or operations and intends to file a rectification application or appeal. No enriched period-over-period, forward-looking, insider, capital allocation, or transaction data was supplied for this filing, so portfolio-level trend analysis cannot be performed from this stream. The materiality score is low (2/10) and sentiment is neutral. The primary implication is a compliance-related contingent liability that is small relative to a large-cap pharma balance sheet, with the key items to track being the appeal outcome and any recurrence of SEZ documentation or input tax credit issues.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior BSE Pharma Sector Regulatory Filings digest from October 02, 2026.
Investment Signals (1)
- Biocon Limited ↓ (NEUTRAL)▲
GST demand order of Rs. 3.22 Cr total exposure (demand, interest, penalty) assessed as immaterial by management, with no operational restrictions beyond penalty
Risk Flags (1)
- Biocon Limited/Tax Compliance↓ [LOW-MEDIUM RISK]▼
GST Order-in-Original for FY 2022-23 cites SEZ endorsement documentation gaps for zero-rated supplies, temporary-vs-permanent input tax reversal errors, and improper Input Service Distribution credit claims; total exposure approx. Rs. 3.22 Cr with final liability still subject to ascertainment
Watch List (1)
-
Track filing of rectification application or appeal against the Visakhapatnam-2 Order-in-Original (order received October 9, 2026); final liability quantification pending
Filing Analyses
(1)
10-10-2026
Biocon Limited disclosed under Regulation 30 that it received an Order-in-Original (DRC-07) from the Office of the Assistant Commissioner (ST), Visakhapatnam-2, confirming a GST demand of Rs. 1,85,28,762, interest of Rs. 1,17,59,033 and penalty of Rs. 18,52,476 for FY 2022-23. The company states there is no material impact on its financials or operations, and intends to file a rectification application or appeal.
- · Issues cited: non-submission of SEZ endorsement documents for zero-rated supplies, input tax reversed temporarily instead of permanently, and improper Input Service Distribution credit claims
- · Order received October 9, 2026 at 15:21 IST; no restriction or sanction imposed beyond the penalty
- · Total quantified exposure is approximately Rs. 3.22 Cr (demand, interest and penalty combined), with final liability subject to ascertainment
Get daily alerts with 1 investment signals, 1 risk alerts and full AI analysis of all 1 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: BSE Pharma Sector Regulatory Filings
October 01, 2026
BSE Pharma Sector Regulatory Filings — October 01, 2026
September 30, 2026
BSE Pharma Sector Regulatory Filings — September 30, 2026
September 28, 2026
BSE Pharma Sector Regulatory Filings — September 28, 2026
September 26, 2026
BSE Pharma Sector Regulatory Filings — September 26, 2026
🇮🇳 More from India
View all →October 03, 2026
India Quarterly Results BSE NSE Announcements — October 03, 2026
India Quarterly Results BSE NSE Announcements
October 03, 2026
India Pre-Market Regulatory Roundup — October 03, 2026
India Pre-Market Regulatory Roundup
October 03, 2026
India Upcoming Corporate Actions BSE NSE — October 03, 2026
India Upcoming Corporate Actions BSE NSE
October 03, 2026
BSE Sensex 30 Stocks Regulatory Filings — October 03, 2026
BSE Sensex 30 Stocks Regulatory Filings